BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther 2021;54:1432-41. [PMID: 34694009 DOI: 10.1111/apt.16663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kwon HJ, Panagos K, Alizadeh M, Bell M, Bourmaf M, Zisman E, Paul P, Sibel L, Wong U. Patients with inflammatory bowel disease are more hesitant about Coronavirus disease 2019 vaccination. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1005121] [Reference Citation Analysis]
2 Chen L, Hu K, Cheng C, Hu Q, Zhang L, An T, Guo Y, Chen S, Duan G. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Colorectal Dis 2022. [PMID: 36271206 DOI: 10.1007/s00384-022-04265-w] [Reference Citation Analysis]
3 Macedo Silva V, Lima Capela T, Freitas M, Cúrdia Gonçalves T, Boal Carvalho P, Dias de Castro F, João Moreira M, Cotter J. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection? Inflamm Bowel Dis 2022:izac187. [PMID: 36099059 DOI: 10.1093/ibd/izac187] [Reference Citation Analysis]
4 Festa S, De Biasio F, Aratari A, Papi C. Intentional treatment with tofacitinib in a patient with severe refractory ulcerative colitis and concomitant Sars-CoV-2 infection. Dig Liver Dis 2022:S1590-8658(22)00666-1. [PMID: 36137935 DOI: 10.1016/j.dld.2022.08.038] [Reference Citation Analysis]
5 Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther 2021;54:1432-41. [PMID: 34694009 DOI: 10.1111/apt.16663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]